ClinicalTrials.gg
RecruitingNCT07840027Updated Sep 24, 2026

Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease

A Phase 1 interventional study of TRB-001 and Placebo in Parkinson Disease (PD) and Idiopathic Parkinson's Disease, sponsored by Tridem Bioscience FlexCo. Recruiting at 1 site in Austria. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Tridem Bioscience FlexCo · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Parkinson Disease with a site in Austria — 10 open to participants now, 16 under way, 2 of them phase 3. Parkinson Disease · Austria.

Planned enrollment
59th of 71
36 · median 189
Started
2026
with 2 others
Phase 1
7 of 87
2 open now
Primary completion
2028-09
later than 11 of 15 live
Registered
87th of 87
by date

Among the 87 studies in Parkinson Disease with a site in Austria, this one is the 59th largest by planned enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 11 of the 15 other live ones, and was the 87th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 87 studies in Parkinson Disease with a site in Austria are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Parkinson Disease with a site in Austria, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.

03

Conditions studied

  • Parkinson Disease (PD)
  • Idiopathic Parkinson's Disease

Browse trials for

Keywords

  • Early idiopathic Parkinson's Disease
  • Randomized Study
  • Placebo-controlled
  • double-blind
  • dose-finding
  • Phase 1b
  • immunogenicity
  • pharmacodynamics
  • Safety
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients aged 40-75 years old. Refer to section 5.3 for reproductive criteria for male and female participants
  2. Diagnosed with idiopathic PD within the previous 4 years based on the MDS-PD criteria. The diagnosis must be confirmed by bradykinesia plus one of the other cardinal signs (resting tremor, rigidity or postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction) being present
  3. Severity ≤2 in the modified Hoehn and Yahr scale
  4. Brain magnetic resonance imaging (MRI) results should be consistent with the diagnosis of PD
  5. If on symptomatic PD medications (L-DOPA (+/- benserazide, carbidopa), COMT inhibitors (entacapone, opicapone), dopamine agonists (pramipexol, ropinirole, rotigotine, apomorphine), MAO-B inhibitors (safinamid, selegiline, rasagiline) or NMDA receptor antagonists (amantadine)), doses must be stable for at least 3 months before study entry
  6. Understands and agrees to comply with the study procedures and provides written

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy, or history of anaphylaxis, to vaccines or their , or kanamycin, if considered relevant by the investigator
  2. Presence or history of disease or immunodeficiency, if considered relevant by the investigator
  3. Presence of active infectious disease (, , or (HIV))
  4. Significant cognitive impairment or clinical dementia, or a (MoCA) score \<26
  5. High suspicion of other parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy, drug induced Parkinsonism and post-encephalitic Parkinsonism
  6. Any relevant systemic illness. This includes cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
  7. Unstable psychiatric illness, including psychosis, suicidal ideation, untreated major depression, schizophrenia, or bipolar affective disorder within 90 days before Visit 1, as determined by the investigator
  8. History of drug or alcohol abuse within the past 5 years
  9. Recent history (≤2 years) of cancer (exceptions: basal cell carcinoma, intraepithelial cervical neoplasia)
  10. for MRI or lumbar puncture
  11. Female patients who are pregnant or lactating
  12. Birthmarks, tattoos, wounds, or skin conditions that may obscure the assessment of injection site reactions
  13. Participation in the active treatment phase of any non-PD clinical trial within 30 days prior to Visit 1
  14. Prior treatment with experimental immunotherapeutics for PD, drugs or treatment with deep brain stimulation. Patient has received or plans to receive any vaccine other than study intervention within 28 days before or 28 days after each study vaccination.
  15. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    low dose (LD)

    20 µg; 0.1 ml

    Biological: TRB-001 · Other: Placebo

  • Experimental
    high dose (HD)

    100 µg; 0.5 ml

    Biological: TRB-001 · Other: Placebo

  • Experimental
    logarithmic dosing (LogD)

    20, 40, and 100 µg; 0.1, 0.2, and 0.5 ml

    Biological: TRB-001 · Other: Placebo

Interventions

  • BiologicalTRB-001

    solution for intradermal injection

  • OtherPlacebo

    solution for intradermal injection

06

What researchers measure

Primary outcomes

  1. To investigate treatment-emergent adverse events at 2 different dose levels (LD, HD) compared to placebo in PD patients over 6 months (safety and tolerability of TRB-001)

    Incidence of local and systemic treatment-emergent adverse events (TEAEs) (occurrence, intensity, duration, and relationship to IMPs) at LD and HD over 6 months (V1-V6) compared to placebo

    Time frame: 6 months

  2. To assess immunogenicity of TRB-001 at 2 different dose levels (LD, HD) in PD patients over 6 months

    Titers of anti-α-synuclein antibodies (immunizing peptide, α synuclein monomer) in blood samples at LD and HD over 6 months (V1-V6) compared to placebo as assessed by ELISA

    Time frame: 6 months

Secondary outcomes

  1. To investigate incidence of Treatment-Emergent Adverse Events compared to placebo in PD patients (Safety and Tolerability of TRB-001)

    Incidence of local and systemic TEAEs at LogD over 6 months (V1-V6) compared to placebo Incidence of local and systemic TEAEs over 18 months (V1-V8) compared to placebo

    Time frame: 6 months 18 months

  2. To assess immunogenicity of TRB-001 in PD patients

    Titers of anti-α-synuclein antibodies (immunizing peptide, α synuclein monomer) in blood samples at LogD over 6 months (V1-V6) compared to placebo as assessed by ELISA

    Time frame: 6 months

  3. To obtain liquid surrogate biomarkers of PD and evaluate their correlation with clinical activity

    Time frame: 6 months 18 months

  4. To assess the efficacy of TRB-001 in delaying motor and non motor symptom progression compared to placebo in PD patients using MDS-UPDRS II (activity of daily life) and MDS-UPDRS III (motor-examination) over 18 months

    Change from baseline in MDS-UPDRS II (activity of daily life) over 18 months (V2, V6-V8) Change from baseline in MDS-UPDRS III (motor-examination) over 18 months (V2, V6-V8)

    Time frame: 18 months

07

Study locations

1 of 1 sites recruiting
  • PROSENEX Studienzentrum an der ATOMOS Klinik Währing
    Vienna, 1180, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 24 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 24, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07840027
Lead sponsor
Tridem Bioscience FlexCo
Responsible party
Sponsor
First posted
Sep 24, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

CEO Tridem
Contact
office@tridem.at
+4368120664069

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion